Evidence map›Paper›PMID 39201354›Full record

ArticleInternational journal of molecular sciences2024

Whole Exome Sequencing of Intermediate-Risk Acute Myeloid Leukemia without Recurrent Genetic Abnormalities Offers Deeper Insights into New Diagnostic Classifications.

Francesca Guijarro, Sandra Castaño-Díez, Carlos Jiménez-Vicente, Marta Garrote, José Ramón Álamo, Marta Gómez-Hernando, Irene López-Oreja, Jordi Morata, Mònica López-Guerra, Cristina López and 6 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Francesca GuijarroHematopathology Section, Pathology Department, Hospital Clínic Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-6376-0929
Sandra Castaño-DíezHematopathology Section, Pathology Department, Hospital Clínic Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-9044-4665
Carlos Jiménez-VicenteInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.ORCID 0000-0002-9548-4305
Marta GarroteHematopathology Section, Pathology Department, Hospital Clínic Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-8571-1466
José Ramón ÁlamoHematopathology Section, Pathology Department, Hospital Clínic Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-8579-082X
Marta Gómez-HernandoHematopathology Section, Pathology Department, Hospital Clínic Barcelona, 08036 Barcelona, Spain.
Irene López-OrejaHematopathology Section, Pathology Department, Hospital Clínic Barcelona, 08036 Barcelona, Spain.
Jordi MorataCentro Nacional de Análisis Genómico (CNAG), 08028 Barcelona, Spain.
Mònica López-GuerraHematopathology Section, Pathology Department, Hospital Clínic Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-5545-0178
Cristina LópezHematopathology Section, Pathology Department, Hospital Clínic Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-6644-1659
Sílvia BeàHematopathology Section, Pathology Department, Hospital Clínic Barcelona, 08036 Barcelona, Spain.
Dolors CostaHematopathology Section, Pathology Department, Hospital Clínic Barcelona, 08036 Barcelona, Spain.
Dolors ColomerHematopathology Section, Pathology Department, Hospital Clínic Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-7486-8484
Marina Díaz-BeyáInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Maria RozmanHematopathology Section, Pathology Department, Hospital Clínic Barcelona, 08036 Barcelona, Spain.
Jordi EsteveInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.

Funding

Instituto de Salud Carlos III PI19/01476, PI22/01660
6 · The paper itself

Abstract

Two new diagnostic classifications of acute myeloid leukemia (AML) were published in 2022 to update current knowledge on disease biology. In previous 2017-edition categories of AML with myelodysplasia-related changes, AML was not otherwise specified, but AML with mutated

Indexed as

Core Binding Factor Alpha 2 SubunitExome SequencingLeukemia, Myeloid, AcuteMutationAdultAgedAged, 80 and overDNA Copy Number VariationsFemaleHumansMaleMiddle AgedMyelodysplastic SyndromesCore Binding Factor Alpha 2 SubunitRUNX1 protein, humanacute myeloid leukemiacopy-number analysisintermediate-risk cytogeneticsInternational Consensus Classificationwhole exome sequencingWorld Health Organization Classification

Identifiers

PMID39201354
PMCPMC11354381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.